Informal Request for ATI Records Previously Released

Organization: Health Canada

Year: 2023

Month: September

Request Number: A-2023-000365

Request Summary: All notice of allegation (NOA) filing dates as outlined under sections 5(2.1)(c)(ii), (iii), and (iv) of the Patented Medicines (Notice of Compliance) Regulations, as well as the date in which the NOA was responded to by the first person for the following drugs, between the specified companies. AstraZeneca v Mylan VIMOVO; Merck Sharp & Dohme v Pharmascience JANUVIA; Teva v Pharmascience COPAXONE; Bristol-Myers Squibb v Mylan Pharmaceuticals SUSTIVA; Pfizer v Mylan Pharmaceuticals CELEBREX; Valeant v Generic Partners GLUMETZA; Janssen v Apotex OPSUMIT; Janssen vSandoz OPSUMIT; Alcon v Cobalt Pharmaceuticals PATANOL; Apotex v Shire VYVANSE; Eli Lilly v Mylan Pharmaceuticals CIALIS; Eli Lilly v Apotex CIALIS; Hoffman-La Roche v Apotex VALCYTE; Les Laboratoires Servier v Apotex VIACORAM; Eli Lilly v Teva ALIMTA; Janssen v Celltrion Healthcare REMICADE; Bayer v Apotex YAZ; Bayer v Cobalt Pharmaceuticals YAZ; Astrazeneca v Mylan Pharmaceuticals ARIMIDEX; Novartis Pharmaceuticals v Cobalt Pharmaceuticals Company ACLASTA; Teva v Janssen VELCADE; Laboratoires Servier v Apotex DIAMICRON MR; VIIV Healthcare v Teva KIVEXA; Gilead Sciences v Apotex TRUVADA; Sunovion Pharmaceuticals v Taro Pharmaceuticals LATUDA; Allergan v Sandoz COMBIGAN; Novartis Pharmaceuticals v Teva ZOMETA CONCENTRATE; Bayer v Sandoz ADEMPAS; Bayer v. Dr. Reddy‘s Laboratories Xarelto; Biomarin Pharmaceutical v. Dr. Reddy’s Laboratories KUVAN; Pfizer v Apotex CELEBREX; Bristol-Myers Squibb v Pharmascience ELIQUIS; Bristol-Myers Squibb & Gilead Sciences v Teva ATRIPLA; Purdue Pharma v Collegium Pharmaceuticals OXYNEO; Genentech v Amgen HERCEPTIN; Hoffmann-La Roche v Sandoz ESBRIET; Alcon v Apotex TRAVATAN Z; Janssen v Apotex INVEGA SUSTENNA; Janssen v Teva INVEGA SUSTENNA; Bristol-myers Squibb v Teva REYATAZ; Novo Nordisk v Teva VICTOZA; Bristol-Myers Squibb v Apotex SPRYCEL; Eli Lilly v NuPharm ZYPREXA; Valeant v Cobalt Pharmaceuticals TIAZAC XC; Eli Lilly v Apotex ADCIRCA; Shire v Cobalt Pharmaceuticals Company ADDERALL XR; AstraZeneca v Teva SEROQUEL XR; Eli Lilly v Hospira Healthcare Corporation ALIMTA; Alcon v Apotex Pataday; Valeant v Apotex GLUMETZA; Novartis Pharmaceuticals v Mylan Pharmaceuticals EXELON; Bristol-Myers Squibb v Sandoz ELIQUIS; Bristol-Myers Squibb v. Apotex ELIQUIS; AstraZeneca v Sandoz ONGLYZA; AstraZeneca v Sandoz KOMBOGLYZE; Takeda v Mylan TECTA; Janssen v Actavis Pharma CONCERTA; Pfizer v. Apotex PRISTIQ; Janssen v Apotex ZYTIGA; Janssen v Apotex ZYTIGA; Janssen v Dr Reddys Laboratories ZYTIGA; Bristol-Myers Squibb v Dr. Reddys Laboratories Zytiga; Janssen v Pharmascience ZYTIGA; Eli Lilly v Mylan CIALIS; Allergan v Apotex ZYMAR; Janssen v Apotex PREZISTA; Allergan v Apotex ACTONEL DR.

Disposition: Disclosed in part

Number of pages: 214

Date modified: